11,050 Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Bought by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,050 shares of the specialty pharmaceutical company's stock, valued at approximately $1,372,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. LSV Asset Management boosted its position in shares of Jazz Pharmaceuticals by 1.5% in the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock valued at $311,699,000 after acquiring an additional 37,108 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after purchasing an additional 320,724 shares during the period. Capital World Investors boosted its holdings in Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after purchasing an additional 104,195 shares during the period. Ameriprise Financial Inc. grew its position in Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after purchasing an additional 315,608 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Jazz Pharmaceuticals by 4.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock worth $195,506,000 after purchasing an additional 72,007 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $0.61 during trading hours on Friday, hitting $106.90. 871,418 shares of the company's stock were exchanged, compared to its average volume of 828,359. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The stock has a market cap of $6.47 billion, a price-to-earnings ratio of 14.25, a price-to-earnings-growth ratio of 4.64 and a beta of 0.33. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. The stock's 50-day moving average is $108.63 and its 200-day moving average is $119.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same period in the prior year, the company earned $2.68 EPS. The firm's revenue was down .5% compared to the same quarter last year. As a group, research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on JAZZ shares. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Morgan Stanley decreased their target price on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $184.00.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer now owns 440,307 shares in the company, valued at approximately $54,487,991.25. The trade was a 0.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Seamus Mulligan bought 100,000 shares of the business's stock in a transaction on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the acquisition, the director now owns 100,000 shares of the company's stock, valued at approximately $9,826,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 3,000 shares of company stock valued at $355,925 over the last ninety days. Insiders own 4.30% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.